In Vivo outlines major trends shaping the top 15 cardiovascular device companies included in the latest Medtech 100 rankings. They include a growing need to reach underserved patient populations, ongoing staffing and other challenges created by the COVID-19 pandemic, and reimbursement obstacles.
The top 15 cardiovascular device makers included in the most recent Medtech 100 rankings are on track to return to their pre-pandemic growth rates and strategies by the end of 2022, but COVID-19 has had a lasting impact on the industry.
The pandemic has highlighted persistent structural inequalities in the health care system, especially in the US, and the large medtech...
Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.
Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.
